A two-phase strategy for treatment of oxidant-dependent cancers

Medical Hypotheses

Volumn 69, Issue 3, 2007, Pages 489-496

  McCarty, Mark F ^a   Barroso Aranda, Jorge ^a   Contreras, Francisco ^a  

^a Oasis of Hope Hospital   (Mexico)

Author keywords

[No Author keywords available]

Indexed keywords

ASCORBIC ACID; CALCITRIOL; CATALASE; HYDROGEN PEROXIDE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; SELENIUM; STRESS ACTIVATED PROTEIN KINASE;

ARTICLE; CANCER THERAPY; CELL KILLING; CELL PROLIFERATION; CYTOTOXICITY; DRUG MEGADOSE; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME INHIBITION; HUMAN; OXIDATIVE STRESS; OXYGENATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR CELL; TUMOR SUPPRESSOR GENE;

ANIMALS; ANTINEOPLASTIC AGENTS; ASCORBIC ACID; CATALASE; HUMANS; HYDROGEN PEROXIDE; MODELS, BIOLOGICAL; NADPH OXIDASE; NEOPLASMS; OXIDANTS; OXYGEN;

EID: 34447288953     PISSN: 03069877     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mehy.2006.12.065     Document Type: Article

References (121)

1. Sun Y. Free radicals, antioxidant enzymes, and carcinogenesis. Free Radic Biol Med 8 (1990) 583-599
2. McCormick M.L., Oberley T.D., Elwell J.H., Oberley L.W., Sun Y., and Li J.J. Superoxide dismutase and catalase levels during estrogen-induced renal tumorigenesis, in renal tumors and their autonomous variants in the Syrian hamster. Carcinogenesis 12 (1991) 977-983
3. Sun Y., Colburn N.H., and Oberley L.W. Depression of catalase gene expression after immortalization and transformation of mouse liver cells. Carcinogenesis 14 (1993) 1505-1510
4. Coursin D.B., Cihla H.P., Sempf J., Oberley T.D., and Oberley L.W. An immunohistochemical analysis of antioxidant and glutathione S-transferase enzyme levels in normal and neoplastic human lung. Histol Histopathol 11 (1996) 851-860
5. Baker A.M., Oberley L.W., and Cohen M.B. Expression of antioxidant enzymes in human prostatic adenocarcinoma. Prostate 32 (1997) 229-233
6. Bostwick D.G., Alexander E.E., Singh R., Shan A., Qian J., Santella R.M., et al. Antioxidant enzyme expression and reactive oxygen species damage in prostatic intraepithelial neoplasia and cancer. Cancer 89 (2000) 123-134
7. Sieron G., Jendryczko A., Drozdz M., and Tomala J. Decreased activities of catalase and glutathione peroxidase and reduced glutathione content in uterine cervix cancer. Ginekol Pol 59 (1988) 681-685
8. Rabilloud T., Asselineau D., Miquel C., Calvayrac R., Darmon M., and Vuillaume M. Deficiency in catalase activity correlates with the appearance of tumor phenotype in human keratinocytes. Int J Cancer 45 (1990) 952-956
9. Kwei K.A., Finch J.S., Thompson E.J., and Bowden G.T. Transcriptional repression of catalase in mouse skin tumor progression. Neoplasia 6 (2004) 440-448
10. Policastro L., Molinari B., Larcher F., Blanco P., Podhajcer O.L., Costa C.S., et al. Imbalance of antioxidant enzymes in tumor cells and inhibition of proliferation and malignant features by scavenging hydrogen peroxide. Mol Carcinog 39 (2004) 103-113
11. Tas F., Hansel H., Belce A., Ilvan S., Argon A., Camlica H., et al. Oxidative stress in breast cancer. Med Oncol 22 (2005) 11-15
12. Finch J.S., Tome M.E., Kwei K.A., and Bowden G.T. Catalase reverses tumorigenicity in a malignant cell line by an epidermal growth factor receptor pathway. Free Radic Biol Med 40 (2006) 863-875
13. Irani K., and Goldschmidt-Clermont P.J. Ras, superoxide and signal transduction. Biochem Pharmacol 55 (1998) 1339-1346
14. Suh Y.A., Arnold R.S., Lassegue B., Shi J., Xu X., Sorescu D., et al. Cell transformation by the superoxide-generating oxidase Mox1. Nature 401 (1999) 79-82
15. Arnold R.S., Shi J., Murad E., Whalen A.M., Sun C.Q., Polavarapu R., et al. Hydrogen peroxide mediates the cell growth and transformation caused by the mitogenic oxidase Nox1. Proc Natl Acad Sci USA 98 (2001) 5550-5555
16. Brar S.S., Kennedy T.P., Sturrock A.B., Huecksteadt T.P., Quinn M.T., Whorton A.R., et al. An NAD(P)H oxidase regulates growth and transcription in melanoma cells. Am J Physiol Cell Physiol 282 (2002) C1212-C1224
17. Brar S.S., Corbin Z., Kennedy T.P., Hemendinger R., Thornton L., Bommarius B., et al. NOX5 NAD(P)H oxidase regulates growth and apoptosis in DU 145 prostate cancer cells. Am J Physiol Cell Physiol 285 (2003) C353-C369
18. Brar S.S., Kennedy T.P., Quinn M., and Hoidal J.R. Redox signaling of NF-kappaB by membrane NAD(P)H oxidases in normal and malignant cells. Protoplasma 221 (2003) 117-127
19. Mitsushita J., Lambeth J.D., and Kamata T. The superoxide-generating oxidase Nox1 is functionally required for Ras oncogene transformation. Cancer Res 64 (2004) 3580-3585
20. Vaquero E.C., Edderkaoui M., Pandol S.J., Gukovsky I., and Gukovskaya A.S. Reactive oxygen species produced by NAD(P)H oxidase inhibit apoptosis in pancreatic cancer cells. J Biol Chem 279 (2004) 34643-34654
21. Dong J.M., Zhao S.G., Huang G.Y., and Liu Q. NADPH oxidase-mediated generation of reactive oxygen species is critically required for survival of undifferentiated human promyelocytic leukemia cell line HL-60. Free Radic Res 38 (2004) 629-637
22. Lim S.D., Sun C., Lambeth J.D., Marshall F., Amin M., Chung L., et al. Increased Nox1 and hydrogen peroxide in prostate cancer. Prostate 62 (2005) 200-207
23. Arnold R.S., Shi J., Murad E., Whalen A.M., Sun C.Q., Polavarapu R., et al. Hydrogen peroxide mediates the cell growth and transformation caused by the mitogenic oxidase Nox1. Proc Natl Acad Sci USA 98 (2001) 5550-5555
24. Arbiser J.L., Petros J., Klafter R., Govindajaran B., McLaughlin E.R., Brown L.F., et al. Reactive oxygen generated by Nox1 triggers the angiogenic switch. Proc Natl Acad Sci USA 99 (2002) 715-720
25. DeYulia Jr. G.J., and Carcamo J.M. EGF receptor-ligand interaction generates extracellular hydrogen peroxide that inhibits EGFR-associated protein tyrosine phosphatases. Biochem Biophys Res Commun 334 (2005) 38-42
26. Seshiah P.N., Weber D.S., Rocic P., Valppu L., Taniyama Y., and Griendling K.K. Angiotensin II stimulation of NAD(P)H oxidase activity: upstream mediators. Circ Res 91 (2002) 406-413
27. Saito S., Frank G.D., Mifune M., Ohba M., Utsunomiya H., Motley E.D., et al. Ligand-independent trans-activation of the platelet-derived growth factor receptor by reactive oxygen species requires protein kinase C-delta and c-Src. J Biol Chem 277 (2002) 44695-44700
28. Catarzi S., Biagioni C., Giannoni E., Favilli F., Marcucci T., Iantomasi T., et al. Redox regulation of platelet-derived-growth-factor-receptor: role of NADPH-oxidase and c-Src tyrosine kinase. Biochim Biophys Acta 1745 (2005) 166-175
29. Meves A., Stock S.N., Beyerle A., Pittelkow M.R., and Peus D. H(2)O(2) mediates oxidative stress-induced epidermal growth factor receptor phosphorylation. Toxicol Lett 122 (2001) 205-214
30. Chen K., Thomas S.R., Albano A., Murphy M.P., and Keaney Jr. J.F. Mitochondrial function is required for hydrogen peroxide-induced growth factor receptor transactivation and downstream signaling. J Biol Chem 279 (2004) 35079-35086
31. Vollgraf U., Wegner M., and Richter-Landsberg C. Activation of AP-1 and nuclear factor-kappaB transcription factors is involved in hydrogen peroxide-induced apoptotic cell death of oligodendrocytes. J Neurochem 73 (1999) 2501-2509
32. Zhou L.Z., Johnson A.P., and Rando T.A. NF kappa B and AP-1 mediate transcriptional responses to oxidative stress in skeletal muscle cells. Free Radic Biol Med 31 (2001) 1405-1416
33. Bram S., Froussard P., Guichard M., Jasmin C., Augery Y., Sinoussi-Barre F., et al. Vitamin C preferential toxicity for malignant melanoma cells. Nature 284 (1980) 629-631
34. Leung P.Y., Miyashita K., Young M., and Tsao C.S. Cytotoxic effect of ascorbate and its derivatives on cultured malignant and nonmalignant cell lines. Anticancer Res 13 (1993) 475-480
35. Sakagami H., Satoh K., Hakeda Y., and Kumegawa M. Apoptosis-inducing activity of vitamin C and vitamin K. Cell Mol Biol (Noisy-le-grand) 46 (2000) 129-143
36. Chen Q., Espey M.G., Krishna M.C., Mitchell J.B., Corpe C.P., Buettner G.R., et al. Pharmacologic ascorbic acid concentrations selectively kill cancer cells: action as a pro-drug to deliver hydrogen peroxide to tissues. Proc Natl Acad Sci USA 102 (2005) 13604-13609
37. Sestili P., Brandi G., Brambilla L., Cattabeni F., and Cantoni O. Hydrogen peroxide mediates the killing of U937 tumor cells elicited by pharmacologically attainable concentrations of ascorbic acid: cell death prevention by extracellular catalase or catalase from cocultured erythrocytes or fibroblasts. J Pharmacol Exp Ther 277 (1996) 1719-1725
38. Iwasaka K., Koyama N., Nogaki A., Maruyama S., Tamura A., Takano H., et al. Role of hydrogen peroxide in cytotoxicity induction by ascorbates and other redox compounds. Anticancer Res 18 (1998) 4333-4337
39. Benade L., Howard T., and Burk D. Synergistic killing of Ehrlich ascites carcinoma cells by ascorbate and 3-amino-1,2,4,-triazole. Oncology 23 (1969) 33-43
40. Riordan N.H., Riordan H.D., Meng X., Li Y., and Jackson J.A. Intravenous ascorbate as a tumor cytotoxic chemotherapeutic agent. Med Hypotheses 44 (1995) 207-213
41. Gonzalez M.J., Miranda-Massari J.R., Mora E.M., Jimenez I.Z., Matos M.I., Riordan H.D., et al. Orthomolecular oncology: a mechanistic view of intravenous ascorbate's chemotherapeutic activity. PR Health Sci J 21 (2002) 39-41
42. Padayatty S.J., and Levine M. Reevaluation of ascorbate in cancer treatment: emerging evidence, open minds and serendipity. J Am Coll Nutr 19 (2000) 423-425
43. Padayatty S.J., Sun H., Wang Y., Riordan H.D., Hewitt S.M., Katz A., et al. Vitamin C pharmacokinetics: implications for oral and intravenous use. Ann Int Med 140 (2004) 533-537
44. Cameron E., and Campbell A. The orthomolecular treatment of cancer. II. Clinical trial of high-dose ascorbic acid supplements in advanced human cancer. Chem Biol Interact 9 (1974) 285-315
45. Cameron E., and Pauling L. Supplemental ascorbate in the supportive treatment of cancer: prolongation of survival times in terminal human cancer. Proc Natl Acad Sci USA 73 (1976) 3685-3689
46. Cameron E., Pauling L., and Leibovitz B. Ascorbic acid and cancer: a review. Cancer Res 39 (1979) 663-681
47. Campbell A., Jack T., and Cameron E. Reticulum cell sarcoma: two complete 'spontaneous' regressions, in response to high-dose ascorbic acid therapy. A report on subsequent progress. Oncology 48 (1991) 495-497
48. Cameron E., and Campbell A. Innovation vs. quality control: an 'unpublishable' clinical trial of supplemental ascorbate in incurable cancer. Med Hypotheses 36 (1991) 185-189
49. Creagan E.T., Moertel C.G., O'Fallon J.R., Schutt A.J., O'Connell M.J., Rubin J., et al. Failure of high-dose vitamin C (ascorbic acid) therapy to benefit patients with advanced cancer. A controlled trial. N Engl J Med 301 (1979) 687-690
50. Moertel C.G., Fleming T.R., Creagan E.T., Rubin J., O'Connell M.J., and Ames M.M. High-dose vitamin C versus placebo in the treatment of patients with advanced cancer who have had no prior chemotherapy. A randomized double-blind comparison. N Engl J Med 312 (1985) 137-141
51. Riordan H.D., Casciari J.J., Gonzalez M.J., Riordan N.H., Miranda-Massari J.R., Taylor P., et al. A pilot clinical study of continuous intravenous ascorbate in terminal cancer patients. PR Health Sci J 24 (2005) 269-276
52. Padayatty S.J., Riordan H.D., Hewitt S.M., Katz A., Hoffer L.J., and Levine M. Intravenously administered vitamin C as cancer therapy: three cases. CMAJ 174 (2006) 937-942
53. Verrazzo G., Coppola L., Luongo C., Sammartino A., Giunta R., Grassia A., et al. Hyperbaric oxygen, oxygen-ozone therapy, and rheologic parameters of blood in patients with peripheral occlusive arterial disease. Undersea Hyperb Med 22 (1995) 17-22
54. Giunta R., Coppola A., Luongo C., Sammartino A., Guastafierro S., Grassia A., et al. Ozonized autohemotransfusion improves hemorheological parameters and oxygen delivery to tissues in patients with peripheral occlusive arterial disease. Ann Hematol 80 (2001) 745-748
55. Bocci V., Larini A., and Micheli V. Restoration of normoxia by ozone therapy may control neoplastic growth: a review and a working hypothesis. J Altern Complem Med 11 (2005) 257-265
56. Valacchi G., and Bocci V. Studies on the biological effects of ozone: 11. Release of factors from human endothelial cells. Mediat Inflamm 9 (2000) 271-276
57. Teicher B.A. Combination of perfluorochemical emulsions and carbogen breathing with cancer chemotherapy. Artif Cells Blood Substit Immobil Biotechnol 22 (1994) 1109-1120
58. Teicher B.A., Schwartz G.N., Dupuis N.P., Kusomoto T., Liu M., Liu F., et al. Oxygenation of human tumor xenografts in nude mice by a perfluorochemical emulsion and carbogen breathing. Artif Cells Blood Substit Immobil Biotechnol 22 (1994) 1369-1375
59. Lowe K.C. Perfluorinated blood substitutes and artificial oxygen carriers. Blood Rev 13 (1999) 171-184
60. Horsman M.R. Nicotinamide and other benzamide analogs as agents for overcoming hypoxic cell radiation resistance in tumours. A review. Acta Oncol 34 (1995) 571-587
61. Rojas A. Radiosensitization with normobaric oxygen and carbogen. Radiother Oncol 20 Suppl. 1 (1991) 65-70
62. Kjellen E., Joiner M.C., Collier J.M., Johns H., and Rojas A. A therapeutic benefit from combining normobaric carbogen or oxygen with nicotinamide in fractionated X-ray treatments. Radiother Oncol 22 (1991) 81-91
63. 2: mitochondria as a convergence point in the death pathway. Free Radic Biol Med 39 (2005) 266-278
64. Koren R., Hadari-Naor I., Zuck E., Rotem C., Liberman U.A., and Ravid A. Vitamin D is a prooxidant in breast cancer cells. Cancer Res 61 (2001) 1439-1444
65. Trump D.L., Hershberger P.A., Bernardi R.J., Ahmed S., Muindi J., Fakih M., et al. Anti-tumor activity of calcitriol: pre-clinical and clinical studies. J Steroid Biochem Mol Biol 89-90 (2004) 519-526
66. Diker-Cohen T., Koren R., and Ravid A. Programmed cell death of stressed keratinocytes and its inhibition by vitamin D: the role of death and survival signaling pathways. Apoptosis 11 (2006) 519-534
67. Hu H., Jiang C., Ip C., Rustum Y.M., and Lu J. Methylseleninic acid potentiates apoptosis induced by chemotherapeutic drugs in androgen-independent prostate cancer cells. Clin Cancer Res 11 (2005) 2379-2388
68. Bozzi A., Mavelli I., Mondovi B., Strom R., and Rotilio G. Differential sensitivity of tumor cells to externally generated hydrogen peroxide. Role of glutathione and related enzymes. Cancer Biochem Biophys 3 (1979) 135-141
69. Rees D.C., Kelsey H., and Richards J.D. Acute haemolysis induced by high dose ascorbic acid in glucose-6-phosphate dehydrogenase deficiency. BMJ 306 (1993) 841-842
70. Gonzalez M.J., Miranda-Massari J.R., Mora E.M., Guzman A., Riordan N.H., Riordan H.D., et al. Orthomolecular oncology review: ascorbic acid and cancer 25 years later. Integr Cancer Ther 4 (2005) 32-44
71. Ursini M.V., Parrella A., Rosa G., Salzano S., and Martini G. Enhanced expression of glucose-6-phosphate dehydrogenase in human cells sustaining oxidative stress. Biochem J 323 (1997) 801-806
72. Robey I.F., Lien A.D., Welsh S.J., Baggett B.K., and Gillies R.J. Hypoxia-inducible factor-1alpha and the glycolytic phenotype in tumors. Neoplasia 7 (2005) 324-330
73. McCarty M.F. Prospects for glycerol-rescued hypoglycemia as a cancer therapy. Med Hypotheses 56 (2001) 286-289
74. Burt M.E., Peters M.L., Brennan M.F., Sato S., Cornblath M., and Adams A. Hypoglycemia with glycerol infusion as antineoplastic therapy: a hypothesis. Surgery 97 (1985) 231-233
75. Wang H.Y., Hochwald S., Port J., Harrison L.E., Ng B., and Burt M. Hypoglycemia with glycerol salvage: a role in anti-neoplastic therapy?. Anticancer Res 15 (1995) 1343-1348
76. Laurent A., Nicco C., Chereau C., Goulvestre C., Alexandre J., Alves A., et al. Controlling tumor growth by modulating endogenous production of reactive oxygen species. Cancer Res 65 (2005) 948-956
77. Fang J., Sawa T., Akaike T., Akuta T., Sahoo S.K., Khaled G., et al. In vivo antitumor activity of pegylated zinc protoporphyrin: targeted inhibition of heme oxygenase in solid tumor. Cancer Res 63 (2003) 3567-3574
78. Lanone S., Bloc S., Foresti R., Almolki A., Taille C., Callebert J., et al. Bilirubin decreases nos2 expression via inhibition of NAD(P)H oxidase: implications for protection against endotoxic shock in rats. FASEB J 19 (2005) 1890-1892
79. Simizu S., Takada M., Umezawa K., and Imoto M. Requirement of caspase-3(-like) protease-mediated hydrogen peroxide production for apoptosis induced by various anticancer drugs. J Biol Chem 273 (1998) 26900-26907
80. Alexandre J., Batteux F., Nicco C., Chereau C., Laurent A., Guillevin L., et al. Accumulation of hydrogen peroxide is an early and crucial step for paclitaxel-induced cancer cell death both in vitro and in vivo. Int J Cancer 119 (2006) 41-48
81. Skapek S.X., Colvin O.M., Griffith O.W., Elion G.B., Bigner D.D., and Friedman H.S. Enhanced melphalan cytotoxicity following buthionine sulfoximine-mediated glutathione depletion in a human medulloblastoma xenograft in athymic mice. Cancer Res 48 (1988) 2764-2767
82. Hamaguchi K., Godwin A.K., Yakushiji M., O'Dwyer P.J., Ozols R.F., and Hamilton T.C. Cross-resistance to diverse drugs is associated with primary cisplatin resistance in ovarian cancer cell lines. Cancer Res 53 (1993) 5225-5232
83. Sasada T., Iwata S., Sato N., Kitaoka Y., Hirota K., Nakamura K., et al. Redox control of resistance to cis-diamminedichloroplatinum (II) (CDDP): protective effect of human thioredoxin against CDDP-induced cytotoxicity. J Clin Invest 97 (1996) 2268-2276
84. Kong Q., Beel J.A., and Lillehei K.O. A threshold concept for cancer therapy. Med Hypotheses 55 (2000) 29-35
85. Ogawa Y., Takahashi T., Kobayashi T., Kariya S., Nishioka A., Ohnishi T., et al. Apoptotic-resistance of the human osteosarcoma cell line HS-Os-1 to irradiation is converted to apoptotic-susceptibility by hydrogen peroxide: a potent role of hydrogen peroxide as a new radiosensitizer. Int J Mol Med 12 (2003) 845-850
86. Fang J., Sawa T., Akaike T., Akuta T., Sahoo S.K., Khaled G., et al. In vivo antitumor activity of pegylated zinc protoporphyrin: targeted inhibition of heme oxygenase in solid tumor. Cancer Res 63 (2003) 3567-3574
87. Fang J., Sawa T., Akaike T., Greish K., and Maeda H. Enhancement of chemotherapeutic response of tumor cells by a heme oxygenase inhibitor, pegylated zinc protoporphyrin. Int J Cancer 109 (2004) 1-8
88. Ramanathan B., Jan K.Y., Chen C.H., Hour T.C., Yu H.J., and Pu Y.S. Resistance to paclitaxel is proportional to cellular total antioxidant capacity. Cancer Res 65 (2005) 8455-8460
89. Chan M.M., Soprano K.J., Weinstein K., and Fong D. Epigallocatechin-3-gallate delivers hydrogen peroxide to induce death of ovarian cancer cells and enhances their cisplatin susceptibility. J Cell Physiol 207 (2006) 389-396
90. 2 but not tumor necrosis factor. J Biol Chem 280 (2005) 19036-19044
91. Goldman E.H., Chen L., and Fu H. Activation of apoptosis signal-regulating kinase 1 by reactive oxygen species through dephosphorylation at serine 967 and 14-3-3 dissociation. J Biol Chem 279 (2004) 10442-10449
92. Shimada K., Nakamura M., Ishida E., Kishi M., Yonehara S., and Konishi N. c-Jun NH2-terminal kinase-dependent Fas activation contributes to etoposide-induced apoptosis in p53-mutated prostate cancer cells. Prostate 55 (2003) 265-280
93. Bae I.H., Kang S.W., Yoon S.H., and Um H.D. Cellular components involved in the cell death induced by cisplatin in the absence of p53 activation. Oncol Rep 15 (2006) 1175-1180
94. Sunayama J., Tsuruta F., Masuyama N., and Gotoh Y. JNK antagonizes Akt-mediated survival signals by phosphorylating 14-3-3. J Cell Biol 170 (2005) 295-304
95. Yoshida K., Yamaguchi T., Natsume T., Kufe D., and Miki Y. JNK phosphorylation of 14-3-3 proteins regulates nuclear targeting of c-Abl in the apoptotic response to DNA damage. Nat Cell Biol 7 (2005) 278-285
96. Tsuruta F., Sunayama J., Mori Y., Hattori S., Shimizu S., Tsujimoto Y., et al. JNK promotes Bax translocation to mitochondria through phosphorylation of 14-3-3 proteins. EMBO J 23 (2004) 1889-1899
97. Lei K., and Davis R.J. JNK phosphorylation of Bim-related members of the Bcl2 family induces Bax-dependent apoptosis. Proc Natl Acad Sci USA 100 (2003) 2432-2437
98. Liu J., and Lin A. Role of JNK activation in apoptosis: a double-edged sword. Cell Res 15 (2005) 36-42
99. Yamamoto K., Ichijo H., and Korsmeyer S.J. BCL-2 is phosphorylated and inactivated by an ASK1/Jun N-terminal protein kinase pathway normally activated at G(2)/M. Mol Cell Biol 19 (1999) 8469-8478
100. Fan M., Goodwin M., Vu T., Brantley-Finley C., Gaarde W.A., and Chambers T.C. Vinblastine-induced phosphorylation of Bcl-2 and Bcl-XL is mediated by JNK and occurs in parallel with inactivation of the Raf-1/MEK/ERK cascade. J Biol Chem 275 (2000) 29980-29985
101. Fuchs S.Y., Adler V., Pincus M.R., and Ronai Z. MEKK1/JNK signaling stabilizes and activates p53. Proc Natl Acad Sci USA 95 (1998) 10541-10546
102. Kolbus A., Herr I., Schreiber M., Debatin K.M., Wagner E.F., and Angel P. c-Jun-dependent CD95-L expression is a rate-limiting step in the induction of apoptosis by alkylating agents. Mol Cell Biol 20 (2000) 575-582
103. Mansouri A., Ridgway L.D., Korapati A.L., Zhang Q., Tian L., Wang Y., et al. Sustained activation of JNK/p38 MAPK pathways in response to cisplatin leads to Fas ligand induction and cell death in ovarian carcinoma cells. J Biol Chem 278 (2003) 19245-19256
104. Eichhorst S.T., Muller M., Li-Weber M., Schulze-Bergkamen H., Angel P., and Krammer P.H. A novel AP-1 element in the CD95 ligand promoter is required for induction of apoptosis in hepatocellular carcinoma cells upon treatment with anticancer drugs. Mol Cell Biol 20 (2000) 7826-7837
105. Bernardini S., Bernassola F., Cortese C., Ballerini S., Melino G., Motti C., et al. Modulation of GST P1-1 activity by polymerization during apoptosis. J Cell Biochem 77 (2000) 645-653
106. Ek A., Strom K., and Cotgreave I.A. The uptake of ascorbic acid into human umbilical vein endothelial cells and its effect on oxidant insult. Biochem Pharmacol 50 (1995) 1339-1346
107. Hampton M.B., and Orrenius S. Dual regulation of caspase activity by hydrogen peroxide: implications for apoptosis. FEBS Lett 414 (1997) 552-556
108. Lee Y.J., and Shacter E. Oxidative stress inhibits apoptosis in human lymphoma cells. J Biol Chem 274 (1999) 19792-19798
109. Shacter E., Williams J.A., Hinson R.M., Senturker S., and Lee Y.J. Oxidative stress interferes with cancer chemotherapy: inhibition of lymphoma cell apoptosis and phagocytosis. Blood 96 (2000) 307-313
110. Salsman S.J., Hensley K., and Floyd R.A. Sensitivity of protein tyrosine phosphatase activity to the redox environment, cytochrome C, and microperoxidase. Antioxid Redox Signal 7 (2005) 1078-1088
111. Kwon J., Lee S.R., Yang K.S., Ahn Y., Kim Y.J., Stadtman E.R., et al. Reversible oxidation and inactivation of the tumor suppressor PTEN in cells stimulated with peptide growth factors. Proc Natl Acad Sci USA 101 (2004) 16419-16424
112. Kim D., Dan H.C., Park S., Yang L., Liu Q., Kaneko S., et al. AKT/PKB signaling mechanisms in cancer and chemoresistance. Front Biosci 10 (2005) 975-987
113. Song G., Ouyang G., and Bao S. The activation of Akt/PKB signaling pathway and cell survival. J Cell Mol Med 9 (2005) 59-71
114. Teicher B.A., Holden S.A., al Achi A., and Herman T.S. Classification of antineoplastic treatments by their differential toxicity toward putative oxygenated and hypoxic tumor subpopulations in vivo in the FSaIIC murine fibrosarcoma. Cancer Res 50 (1990) 3339-3344
115. Teicher B.A. Hypoxia and drug resistance. Cancer Metast Rev 13 (1994) 139-168
116. Vaupel P., Thews O., and Hoeckel M. Treatment resistance of solid tumors: role of hypoxia and anemia. Med Oncol 18 (2001) 243-259
117. Brown L.M., Cowen R.L., Debray C., Eustace A., Erler J.T., Sheppard F.C., et al. Reversing hypoxic cell chemoresistance in vitro using genetic and small molecule approaches targeting hypoxia inducible factor-1. Mol Pharmacol 69 (2006) 411-418
118. Erler J.T., Cawthorne C.J., Williams K.J., Koritzinsky M., Wouters B.G., Wilson C., et al. Hypoxia-mediated down-regulation of Bid and Bax in tumors occurs via hypoxia-inducible factor 1-dependent and -independent mechanisms and contributes to drug resistance. Mol Cell Biol 24 (2004) 2875-2889
119. Zhu H., Chen X.P., Luo S.F., Guan J., Zhang W.G., and Zhang B.X. Involvement of hypoxia-inducible factor-1-alpha in multidrug resistance induced by hypoxia in HepG2 cells. J Exp Clin Cancer Res 24 (2005) 565-574
120. Cao S., Durrani F.A., and Rustum Y.M. Selective modulation of the therapeutic efficacy of anticancer drugs by selenium containing compounds against human tumor xenografts. Clin Cancer Res 10 (2004) 2561-2569
121. Fakih M., Cao S., Durrani F.A., and Rustum Y.M. Selenium protects against toxicity induced by anticancer drugs and augments antitumor activity: a highly selective, new, and novel approach for the treatment of solid tumors. Clin Colorectal Cancer 5 (2005) 132-135